Analytical Data
-
Gene name
SIGLEC6
- Application
-
Alternative Names
CD33L; CD33L1; OBBP1; OB-BP1; SIGLEC-6; CD327; CD33 antigen-like 1; Obesity-binding protein 1
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43699
-
Expression Region
Gln27~Val331
-
Molecular Weight
48kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-6 (Sialic acid-binding Ig-like lectin 6) is a member of the Siglec family of proteins, which are primarily involved in the recognition of sialic acid-containing glycoconjugates on cell surfaces. Research on recombinant Siglec-6 has gained attention due to its crucial role in modulating immune responses, especially in the context of tumors and certain hematological malignancies. Siglec-6 is predominantly expressed on the surface of human immune cells, including B cells and macrophages, and is linked to the regulation of immune cell activities. Studies have shown that Siglec-6 can inhibit immune cell activation and promote tolerance, making it an essential player in both adaptive and innate immunity. Its unique expression pattern and influence on the immune microenvironment have led to interest in its potential as a therapeutic target for improving immune responses against cancers and autoimmune diseases. Additionally, understanding the structural and functional attributes of recombinant Siglec-6 can provide insights into its interactions with various ligands and its signaling mechanisms. This research holds promise for the development of novel immunotherapeutic strategies aimed at harnessing or modulating the function of Siglec-6 to enhance anti-tumor immunity or restore immune balance in pathological conditions. Overall, the exploration of recombinant Siglec-6 represents a significant advancement in the fields of immunology and therapeutic development, opening avenues for innovative treatments based on the manipulation of sialic acid-mediated immune regulation.
